Recent advances in testicular germ cell tumours.
biomarkers
genetic hallmarks
germ cell cancer
novel treatments
testicular germ cell tumours
Journal
Faculty reviews
ISSN: 2732-432X
Titre abrégé: Fac Rev
Pays: England
ID NLM: 101769226
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
24
9
2021
pubmed:
25
9
2021
medline:
25
9
2021
Statut:
epublish
Résumé
Testicular germ cell tumours (TGCTs) are the most common solid tumours in young men and have an excellent overall cure rate and prognosis. In most patients, localised disease is cured by surgery alone, and a minority of patients receive short-course adjuvant chemotherapy to reduce the risk of further relapse. Also, in about 80% of patients, metastatic disease can be cured by systemic cisplatin-based chemotherapy. Unfortunately, for a proportion of patients, the disease exhibits platinum resistance and relapse occurs. Despite further lines of systemic treatment, cure can be difficult to achieve in these patients and ultimately about 20% of them will die from disease progression. Addressing the mechanisms underpinning platinum resistance is critical to improving the survival and chances of cure for these patients. This review describes the latest advances in TGCT research, focusing on the identification of novel biomarkers, genetic characteristics and exploring novel treatments.
Identifiants
pubmed: 34557871
doi: 10.12703/r/10-67
pmc: PMC8441995
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
67Informations de copyright
Copyright: © 2021 Reid et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.No competing interests were disclosed.No competing interests were disclosed.
Références
J Clin Oncol. 2000 Mar;18(6):1181-6
pubmed: 10715286
Cancer. 2015 May 1;121(9):1463-8
pubmed: 25522918
J Clin Oncol. 2012 Mar 10;30(8):800-5
pubmed: 22291076
Br J Cancer. 2001 Jul 20;85(2):213-20
pubmed: 11461079
Invest New Drugs. 2010 Aug;28(4):523-8
pubmed: 19547919
Eur Urol. 2016 Jul;70(1):93-105
pubmed: 26935559
Lancet. 2006 Mar 4;367(9512):754-65
pubmed: 16517276
Clin Genitourin Cancer. 2016 Dec;14(6):504-510
pubmed: 27055371
Invest New Drugs. 2022 Oct;40(5):1087-1094
pubmed: 35759134
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Ann Intern Med. 1977 Sep;87(3):293-8
pubmed: 71004
J Clin Oncol. 1997 Feb;15(2):594-603
pubmed: 9053482
Nat Commun. 2015 Jan 22;6:5973
pubmed: 25609015
Invest New Drugs. 2013 Aug;31(4):1016-22
pubmed: 23417696
Nat Genet. 2017 Jul;49(7):1141-1147
pubmed: 28604732
Nat Rev Urol. 2016 Jul;13(7):409-19
pubmed: 27296647
J Clin Oncol. 2019 Nov 20;37(33):3090-3098
pubmed: 31553692
Cell Rep. 2018 Jun 12;23(11):3392-3406
pubmed: 29898407
Nature. 2016 Nov 30;540(7631):114-118
pubmed: 27905446
J Clin Oncol. 2005 Sep 20;23(27):6549-55
pubmed: 16170162
J Clin Oncol. 2019 Jun 1;37(16):1412-1423
pubmed: 30875280
Cancer Res. 2009 Dec 15;69(24):9360-6
pubmed: 19951990
Nat Genet. 2017 Jul;49(7):1133-1140
pubmed: 28604728
Nat Commun. 2020 May 4;11(1):2189
pubmed: 32366847
Cancer Med. 2021 Jan;10(1):156-163
pubmed: 33135391
J Clin Oncol. 2016 Nov 20;34(33):4000-4007
pubmed: 27646943
Nat Rev Urol. 2020 Apr;17(4):201-213
pubmed: 32157202
J Clin Oncol. 1998 Jul;16(7):2500-4
pubmed: 9667270
Nat Rev Urol. 2016 Dec;13(12):715-725
pubmed: 27754472
J Clin Oncol. 2017 Apr 1;35(10):1096-1102
pubmed: 27870561
Eur Urol. 2019 Nov;76(5):615-623
pubmed: 31324498
Lancet. 1982 Dec 11;2(8311):1349
pubmed: 6128640
N Engl J Med. 2007 Jul 26;357(4):340-8
pubmed: 17652649
Cancer Treat Rev. 2020 Aug;88:102054
pubmed: 32593915
JAMA. 2008 Feb 13;299(6):672-84
pubmed: 18270356
Crit Rev Oncol Hematol. 2019 Nov;143:130-138
pubmed: 31634730
Mol Oncol. 2013 Dec;7(6):1083-92
pubmed: 24012110
Ann Oncol. 2017 Jun 1;28(6):1346-1351
pubmed: 28383677
N Engl J Med. 1997 Jul 24;337(4):242-53
pubmed: 9227931
Am J Clin Pathol. 2011 Jan;135(1):119-25
pubmed: 21173133
Cancer Res. 2010 Apr 1;70(7):2911-23
pubmed: 20332240
J Cancer Res Clin Oncol. 2019 Mar;145(3):717-723
pubmed: 30232558
J Hematol Oncol. 2014 Aug 01;7:52
pubmed: 25085632
Urol Oncol. 2016 Mar;34(3):122.e17-22
pubmed: 26612480
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32188704
Ann Oncol. 2005 Jul;16(7):1152-9
pubmed: 15928070
Am J Clin Oncol. 2006 Feb;29(1):12-3
pubmed: 16462496
Nat Rev Cancer. 2019 Sep;19(9):522-537
pubmed: 31413324
Ann Oncol. 2011 Dec;22(12):2654-2660
pubmed: 21415240
Sci Rep. 2015 Sep 09;5:13889
pubmed: 26349679
Ann Oncol. 2018 Jan 1;29(1):209-214
pubmed: 29045540
Cancer. 1991 Mar 1;67(5):1305-10
pubmed: 1703917
Oncologist. 2018 Mar;23(3):316-323
pubmed: 29222199
J Clin Oncol. 2010 Jul 10;28(20):3388-404
pubmed: 20530278
Eur Urol. 2020 Feb;77(2):290-292
pubmed: 31699528
J Clin Oncol. 2010 Apr 1;28(10):1706-13
pubmed: 20194867
Invest New Drugs. 2019 Aug;37(4):748-754
pubmed: 31152292
Clin Genitourin Cancer. 2016 Aug;14(4):261-264.e4
pubmed: 27105722
Eur Urol. 2019 Jan;75(1):201-203
pubmed: 30243800
J Urol. 2018 Jul;200(1):126-135
pubmed: 29474847